Hematology

Top news of the week in oncology and cancer drug development.

Multiple clinical trials of vadastuximab talirine have been placed on clinical hold by the FDA.

ASN003 demonstrated potent action against tumor growth.

Hispanic newborns that develop acute lymphoblastic leukemia are 5.9% times more likely to have a cytomegalovirus infection at birth.

Cancer accounts for more years of life lost than any other cause of death.

Association between cancer diagnosis and suicide on a population level suggested.

Relapsed or refractory leukemia patients who received CC-486 had a 38% overall response rate.

Myeloproliferative neoplasms may negatively affect the physical and mental health of patients.

Thioguanine and decitabine combination therapy show positive results in phase 1 trial.

Patients share their personal stories with Specialty Pharmacy Times.

Top news of the week in oncology and cancer drug development.

Regular use of over-the-counter, anti-inflammatory drugs associated with an increased risk of death in patients with cancer.

Investigative drug may improve overall survival and reduce chemotherapy-induced heart damage in children with acute myelogenous leukemia.

Genetically engineered T cells show efficacy preventing acute myeloid leukemia relapse.

Novel immunotherapy shows promise treating patients with leukemia at high-risk of relapse.

Top news of the week in oncology and cancer drug development.

Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.

Switching Tasigna elicited a long-term response rate in patients with leukemia even after discontinuing treatment.

Switching from Glivec to Tasigna elicited a long-term response rate in patients with leukemia.

Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.

Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.

Checkpoint inhibitor resistance remains an issue in cancer therapy.

Top news of the week in oncology and cancer drug development.

Myeloma Genome Project to create the largest dataset of molecular profiling for patients with multiple myeloma.

Partnership between Clearbrdige BioMedics and John Wayne Cancer Institute will initially focus on melanoma.